Profil
Dr. Jackson joined us in January 2001.
He previously was the Director of Research and Development and a member of the Board of Directors at Celltech Group plc.
He was also the Executive Director of Research and Development, the Chief Operating Officer and a member of the Board of Directors at Chiroscience Group plc, which was acquired by Celltech in 1999.
Before these appointments, he was Vice President of Research and Development at Agouron Pharmaceuticals, Inc., and headed cancer research at DuPont Pharmaceuticals and Warner-Lambert Company.
He holds a B.A.
from the University of Cambridge and a Ph.D.
from the University of London, Institute of Cancer Research.
Anciens postes connus de Robert Jackson
| Sociétés | Poste | Fin |
|---|---|---|
Cyclacel Group Plc
 Cyclacel Group Plc Pharmaceuticals: MajorHealth Technology Cyclacel Group Plc designs and develops small molecule drugs. The company developed small molecule drugs act on key cell cycle regulators to stop uncontrolled cell division in cancer and other diseases involving abnormal cell proliferation. Cyclacel Group Plc was founded by Professor Sir David Lane in 1996 and is headquartered in Dundee, UK. | Directeur Technique/Scientifique/R&D | 15/10/2008 |
Formation de Robert Jackson
| University of Cambridge | Undergraduate Degree |
| University of London | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Cyclacel Group Plc
Cyclacel Group Plc Pharmaceuticals: MajorHealth Technology Cyclacel Group Plc designs and develops small molecule drugs. The company developed small molecule drugs act on key cell cycle regulators to stop uncontrolled cell division in cancer and other diseases involving abnormal cell proliferation. Cyclacel Group Plc was founded by Professor Sir David Lane in 1996 and is headquartered in Dundee, UK. | Health Technology |
